Molecular Partners announces publication of its clinical phase I/II trial of MP0112 in DME

January 17, 2013

Molecular Partners announced today that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with Diabetic Macular Edema (DME) have been published on-line in The American Journal of Ophthalmology (AJO). In this study, MP0112 was shown to be safe, and to stabilize or improve visual acuity and reduce retinal edema for up to 12 to 16 weeks.